Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial. (linkinghub.elsevier.com)

Authors: Faust SN … Noviello S Journal: Lancet Infectious Diseases Published: 2026-10-01 DOI: https://doi.org/10.1016/S1473-3099(26)00470-6